Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Carotta

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Nature Communications|August 15, 2014
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cellsPriyanka Sathe, Rebecca B Delconte, Fernando Souza-Fonseca-Guimaraes, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Immunity|January 23, 2016
The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15Rebecca B Delconte, Wei Shi, Priyanka Sathe, et al.
Cell|November 2, 2019
Landscape and Dynamics of Single Immune Cells in Hepatocellular CarcinomaQiming Zhang, Yao He, Nan Luo, et al.
Nature Cancer|February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanomaLisa Haas, Anais Elewaut, Camille L Gerard, et al.
Cell Reports. Medicine|August 26, 2025
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer modelsKsenija Slavic Obradovic, Florian Ebner, Artem V Artemov, et al.
Nature Immunology|November 24, 2015
Complementarity and redundancy of IL-22-producing innate lymphoid cellsLucille C Rankin, Mathilde J H Girard-Madoux, Cyril Seillet, et al.
Nature Immunology|December 12, 2023
Author Correction: CIS is a potent checkpoint in NK cell-mediated tumor immunityRebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, et al.
Nature Immunology|May 24, 2016
CIS is a potent checkpoint in NK cell-mediated tumor immunityRebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Nature Communications|August 15, 2014
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cellsPriyanka Sathe, Rebecca B Delconte, Fernando Souza-Fonseca-Guimaraes, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Immunity|January 23, 2016
The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15Rebecca B Delconte, Wei Shi, Priyanka Sathe, et al.
Cell|November 2, 2019
Landscape and Dynamics of Single Immune Cells in Hepatocellular CarcinomaQiming Zhang, Yao He, Nan Luo, et al.
Nature Cancer|February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanomaLisa Haas, Anais Elewaut, Camille L Gerard, et al.
Cell Reports. Medicine|August 26, 2025
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer modelsKsenija Slavic Obradovic, Florian Ebner, Artem V Artemov, et al.
Nature Immunology|November 24, 2015
Complementarity and redundancy of IL-22-producing innate lymphoid cellsLucille C Rankin, Mathilde J H Girard-Madoux, Cyril Seillet, et al.
Nature Immunology|December 12, 2023
Author Correction: CIS is a potent checkpoint in NK cell-mediated tumor immunityRebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, et al.
Nature Immunology|May 24, 2016
CIS is a potent checkpoint in NK cell-mediated tumor immunityRebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, et al.
Pageof 5